Key Takeaways
- • CVC Capital Partners and Groupe Bruxelles Lambert (GBL) launched a €10.7 billion all-cash tender offer to take Italian pharmaceutical company Recordati private at €51.29 per share ex-dividend, representing a 12.89% premium to the company's prior valuation.
- • The transaction values Recordati at approximately €10.7–10.9 billion (equivalent to $12.4–12.7 billion USD), with the offer directed at delisting the drugmaker from Euronext Milan.
- • CVC Capital initially sought co-investors to help finance the acquisition, underscoring the scale of the deal and the consortium's strategy to distribute capital requirements across multiple parties.
- • The all-cash structure and indiscriminate tender approach signal a straightforward acquisition path, with major legal advisors (Latham & Wise, White & Case) supporting the transaction mechanics.
- • Recordati represents a significant bolt-on acquisition for CVC, consistent with the firm's European healthcare and specialty pharma investment thesis.
Summary
CVC Capital Partners and Belgian investment group Groupe Bruxelles Lambert launched a €10.7 billion all-cash tender offer to acquire Italian pharmaceutical manufacturer Recordati, seeking to take the company private. The consortium fixed the offer price at €51.29 per share in cash on an ex-dividend basis, representing a 12.89% premium to Recordati's prior trading levels. The total enterprise value of the transaction ranges between €10.7 billion and €10.9 billion, equivalent to approximately $12.4–12.7 billion in U.S. dollar terms.
The tender offer was structured as a non-discriminatory, all-cash bid directed at all Recordati shareholders and aimed at achieving a delisting from Euronext Milan, where the company's shares are listed exclusively. CVC Capital initially pursued co-investors to co-finance the acquisition, reflecting the transaction's significant scale and capital intensity. Major international legal advisors, including Latham & Wise and White & Case, supported the consortium on transaction structuring and regulatory compliance.
The offer underscores CVC Capital's continued focus on European pharmaceutical and specialty healthcare assets. Recordati, as an established Italian drugmaker, represents a platform acquisition aligned with CVC's portfolio strategy in the pharmaceutical sector. The all-cash tender structure and premium valuation suggest both sponsors viewed the asset as strategically valuable and sought certainty of closing to secure shareholder acceptance.
The tender offer was structured as a non-discriminatory, all-cash bid directed at all Recordati shareholders and aimed at achieving a delisting from Euronext Milan, where the company's shares are listed exclusively. CVC Capital initially pursued co-investors to co-finance the acquisition, reflecting the transaction's significant scale and capital intensity. Major international legal advisors, including Latham & Wise and White & Case, supported the consortium on transaction structuring and regulatory compliance.
The offer underscores CVC Capital's continued focus on European pharmaceutical and specialty healthcare assets. Recordati, as an established Italian drugmaker, represents a platform acquisition aligned with CVC's portfolio strategy in the pharmaceutical sector. The all-cash tender structure and premium valuation suggest both sponsors viewed the asset as strategically valuable and sought certainty of closing to secure shareholder acceptance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.